Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of MK-0616 in Adults With Hypercholesterolemia
jRCT2031230320Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2023
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia and atherosclerotic disease comparing MK-0616 20 mg QD with Placebo (2 arms). Primary endpoints: Mean percent change from baseline in LDL-C at Week 24, Number of participants with one or more adverse events and 1 more. Started Sep 2023; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemiaatherosclerotic disease
Beyond the preview
Go deeper on jRCT2031230320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230320.